Concussion, Brain, Post-Concussion Syndrome, Vascular System Injuries
Conditions
Keywords
Sildenafil, Concussion, CBF, CVR
Brief summary
About 300,000 people are hospitalized for traumatic brain injury (TBI) each year. After TBI, secondary brain injury escalates due in part to heightened levels of oxidant injury, inflammation, and vascular injury. Traumatic cerebral vascular injury (TCVI) may begin almost immediately after the primary injury and evolve into chronic neurodegenerative conditions. TCVI is a very complex TBI endophenotype and microvascular injuries have been described in a plethora of animal and human TBI studies. These injuries consist of endothelial injury, disruption of the blood brain barrier (BBB), a reduction of capillary density, intravascular microthrombi, and white-matter degeneration. Recently, use of magnetic resonance imaging (MRI)-Blood Oxygen Level Dependent (BOLD) combined with hypercapnia (high spatial and temporal resolution) by our research group has proven to be more sensitive at measuring alterations of cerebral blood flow (CBF) in TBI subjects. The goal of the proposed research is to test the efficacy of Viagra® (sildenafil) at normalizing CBF and improving cognitive outcomes in people that have experienced a TBI. Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor that has previously been administered as a therapy for high blood pressure and erectile dysfunction. In people that have been affected by stroke-induce neurotrauma, sildenafil improved CBF and was found to be neuroprotective. With respect to chronic TBI, previous studies have demonstrated that sildenafil therapy potentiates cardiovascular reactivity (CVR) in areas of the brain with damaged endothelium. In this proposal, the investigators will test the hypothesis that sildenafil treatment in boxers/Mixed Martial Arts (MMA) fighters soon after concussion normalizes CBF, potentiates CVR, reduces post-concussion symptoms, and improves cognition.
Detailed description
In this study, 100 professional boxers that experience a concussion will be enrolled, randomized to either placebo or sildenafil (60mg) drug treatment, and arterial spin labeling and BOLD-MRI with hypercapnia will used to assess CBF and CVR, respectively. Symptom reporting, blood biomarkers, and neuropsychological testing will also be conducted. The timepoints for this study are baseline (pre-fight), and once between days 1 and 3 and day 30 after injury.
Interventions
DRUGSildenafil Citrate
Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)
DRUGPlacebo oral capsule
Placebo once (Group 1) or daily for 2 weeks (Group 2)
Sponsors
University of Texas Southwestern Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Investigators associated with this study will not have access to the randomization schedule. The principal investigator, study team, and study subjects will be blinded in this study.
Intervention model description
This study is a placebo-controlled, double-blinded clinical trial. Randomization will be 1:1 sildenafil:placebo, and will be in blocks of 10. In this study, 100 boxers and 80 controls will be enrolled and randomized.
Eligibility
Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
For Athletes 1. Age 18-35 2. Male or female professional boxers/MMA fighters 3. Ability to undergo MR imaging procedures 4. At least one of the following: 1. Knockout (KO)/Technical Knockout (TKO) scored by fight referee. 2. Greater than 25 blows to the head. 5. Significant post-concussive symptoms (Symptom Score \> 1 on at least 3 items from the Rivermead Post-Concussion Questionnaire) For Controls 1. Age 18-35 2. Male of female who do not participate in contact sports 3. Screen negative for mild TBI (mTBI) using Ohio State TBI Identification
Exclusion criteria
1. Contraindication to sildenafil which includes the following: 1. Current use of organic nitrate vasodilators 2. Use of ritonavir (HIV-protease inhibitor) 3. Current use of erythromycin, ketoconazole, or itraconazole 4. Current use of cimetidine 5. Current resting hypotension (BP \< 90/50 mm Hg) 6. Current severe renal insufficiency (Creatinine Clearance \< 30 milliliters/minute) 7. Current hepatic cirrhosis 8. Current cardiac failure or coronary artery disease causing unstable angina 9. Retinitis pigmentosa 10. Known hypersensitivity or allergy to sildenafil of any of its components 2. Daily therapy with a PDE5 inhibitor within the past 2 months 3. Immediate hospitalization for severe concussion 4. History of neurological or psychiatric disorder not related to TBI 5. Known inclusion in another interventional clinical trial 6. Subjects with metal implants that would interfere with the MR imaging procedures 7. Sickle cell disease 8. History of priapism
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Arterial Spin Labeling | 3 years | Prior to and after sildenafil treatment (60mg) cerebral blood flow will be measured in the athletes and healthy controls. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rivermead Post Concussion Symptoms Questionnaire (RPQ) | 3 years | This test will measure a range of injury severities: 0= Not experienced at all 1. No more of a problem 2. A mild problem 3. A moderate problem 4. A severe problem Improvement or worsening of symptoms (headaches, nausea, fatigue, feeling depressed, light sensitivity, double vision, etc.) will be recorded. The combined score from all symptoms will be recorded at the indicated time-points. |
| Hopkins Verbal Learning Task (HVLT) | 3 years | Using the HVLT, performance in learning and memory will be measured in concussed athletes and healthy controls. |
| BOLD MRI With Hypercapnia | 3 years | Before and after sildenafil treatment, cerebrovascular reactivity will be measured in the athletes and healthy controls. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Oral Capsule If randomized to placebo, the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
Placebo oral capsule: Placebo once (Group 1) or daily for 2 weeks (Group 2) | 0 |
| Sildenafil Citrate If randomized to sildenafil (60mg), the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
Sildenafil Citrate: Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2) | 0 |
| Total | 0 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | enrolled but didn't start | 1 | 0 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 |
Outcome results
Primary
Arterial Spin Labeling
Prior to and after sildenafil treatment (60mg) cerebral blood flow will be measured in the athletes and healthy controls.
Time frame: 3 years
Population: The PI has left the institution, all efforts to locate the data have been exhausted and therefore no results are available to be reported
Secondary
BOLD MRI With Hypercapnia
Before and after sildenafil treatment, cerebrovascular reactivity will be measured in the athletes and healthy controls.
Time frame: 3 years
Population: The PI has left the institution, all efforts to locate the data have been exhausted and therefore no results are available to be reported
Secondary
Hopkins Verbal Learning Task (HVLT)
Using the HVLT, performance in learning and memory will be measured in concussed athletes and healthy controls.
Time frame: 3 years
Population: The PI has left the institution, all efforts to locate the data have been exhausted and therefore no results are available to be reported
Secondary
Rivermead Post Concussion Symptoms Questionnaire (RPQ)
This test will measure a range of injury severities: 0= Not experienced at all 1. No more of a problem 2. A mild problem 3. A moderate problem 4. A severe problem Improvement or worsening of symptoms (headaches, nausea, fatigue, feeling depressed, light sensitivity, double vision, etc.) will be recorded. The combined score from all symptoms will be recorded at the indicated time-points.
Time frame: 3 years
Population: The PI has left the institution, all efforts to locate the data have been exhausted and therefore no results are available to be reported